Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investment Analysts’ new coverage for Tuesday, April 9th: Guggenheim initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN). Guggenheim issued a buy rating and a $55.00 price target on the stock. Needham & Company LLC assumed coverage on shares of Amkor Technology (NASDAQ:AMKR). The firm issued a buy rating and a $40.00 price target on […]
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) traded down 5.6% on Wednesday . The company traded as low as $36.80 and last traded at $37.02. 583,722 shares were traded during trading, a decline of 48% from the average session volume of 1,126,938 shares. The stock had previously closed at $39.21. Analyst […]
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and NanoString Technologies (NASDAQ:NSTG – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Valuation and Earnings This table compares Adaptimmune […]
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the […]